Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 161.05B | 161.00B | 145.30B | 118.18B | 107.28B |
Gross Profit | 35.38B | 36.66B | 34.20B | 29.04B | 26.89B |
EBITDA | 23.32B | 28.63B | 28.14B | 16.88B | 12.90B |
Net Income | 13.59B | 18.02B | 16.33B | 9.02B | 6.62B |
Balance Sheet | |||||
Total Assets | 275.47B | 226.94B | 204.60B | 169.17B | 154.86B |
Cash, Cash Equivalents and Short-Term Investments | 27.40B | 27.08B | 22.30B | 20.05B | 19.39B |
Total Debt | 74.26B | 45.76B | 34.93B | 22.39B | 19.74B |
Total Liabilities | 122.53B | 87.09B | 82.61B | 59.22B | 50.90B |
Stockholders Equity | 145.92B | 133.02B | 115.47B | 103.89B | 98.41B |
Cash Flow | |||||
Free Cash Flow | -25.91B | -4.06B | -9.14B | -2.46B | -1.16B |
Operating Cash Flow | -16.73B | 4.76B | -1.16B | 4.48B | 4.53B |
Investing Cash Flow | -8.76B | -10.10B | -7.82B | -5.31B | -4.73B |
Financing Cash Flow | 23.61B | 6.86B | 5.62B | 439.00M | 5.07B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | ¥39.40B | 9.91 | 2.34% | 4.52% | 9.37% | ||
78 Outperform | ¥192.64B | 13.68 | 2.31% | 0.50% | -8.77% | ||
76 Outperform | ¥26.55B | 10.88 | 3.48% | 10.02% | 56.26% | ||
74 Outperform | ¥97.33B | 9.07 | 3.49% | 8.46% | 74.58% | ||
69 Neutral | ¥105.84B | 9.66 | 4.03% | 10.07% | -38.38% | ||
44 Neutral | AU$1.47B | -5.90 | -41.17% | 4.21% | -3.35% | -41.14% |
Kumiai Chemical Industry Co., Ltd. reported its consolidated financial results for the six months ending April 30, 2025, showing a 9.2% increase in net sales compared to the previous year. However, the company experienced a significant decline in ordinary profit and profit attributable to owners of the parent, with decreases of 36.2% and 32.7% respectively, indicating challenges in profitability despite increased sales.
Kumiai Chemical Industry Co., Ltd. has revised its earnings forecast for the second quarter of the fiscal year ending October 31, 2025, due to increased net sales driven by advanced shipments to overseas markets in its agricultural chemicals and agriculture-related business. While operating income is expected to rise significantly, ordinary and net income remain largely unchanged due to foreign exchange losses from the yen’s appreciation. The full-year earnings forecast remains unchanged, with potential revisions to be disclosed if necessary.